Inhibitory effect of a caerulein-like peptide on human gastric secretion.

@article{Agosti1976InhibitoryEO,
  title={Inhibitory effect of a caerulein-like peptide on human gastric secretion.},
  author={Andrea Agosti and G. Missale and Giulio Bertaccini},
  journal={European journal of pharmacology},
  year={1976},
  volume={38 1},
  pages={
          193-5
        }
}
2 Citations
Reciprocal effect of unsulfated and sulfated forms of cholecystokinin-octapeptide on gastric acid secretion in the rat.
TLDR
It is concluded that lack of sulfation of the tyrosine residue in the seventh position does not exclude CCK-8 from occupying the gastrin receptor; but does prevent the hormone-receptor interaction that leads to the secretory response.
Pharmacology, Clinical Uses, and Adverse Effects of Ceruletide, A Cholecystokinetic Agent
TLDR
In therapeutic doses the adverse effects noted are mild, transient extensions of the drug's pharmacologic actions and are manifest as nausea, vomiting, abdominal pain, and rarely hypotension and tachycardia.

References

SHOWING 1-3 OF 3 REFERENCES
Inhibition of gastric acid secretion in man by peptide analogues of cholecystokinin.
TLDR
Screening of related peptides might yield a specific competitive inhibitor of gastrin with even less stimulatory action than was noted with those tested.